ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Tingting You
Matched on ORCID iD 0000-0002-7506-9737; OpenAlex author ID A5101871197, A5121331631. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers
Papers 7
- Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Stud… Co-author DOI 10.1002/mco2.70829↗
- Inhibition of Gemcitabine-Induced Autophagy in Cancer-Associated Fibroblasts Reduces Collagen I and Enhances Chemotherapeutic Efficacy in Pancreatic Cancer. Co-author DOI 10.1177/15473287261442512↗
- Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. Co-author DOI 10.1177/17588359261470681↗
- S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure. Co-author DOI 10.1177/17588359251378698↗
- [Comparison of adjuvant S-1 plus gemcitabine with S-1 monotherapy for pancreatic adenocarcinoma: real-world data]. Co-author DOI 10.3760/cma.j.cn112152-20250310-00103↗
- The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s11764-023-01429-7↗
- A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenoca… Co-author DOI 10.1186/s12885-023-11464-3↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chunmei Bai · 7 shared papers, 2023–2026 · strength 1.86
- Paper Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. DOI 10.1177/17588359261470681↗
- Paper Inhibition of Gemcitabine-Induced Autophagy in Cancer-Associated Fibroblasts Reduces Collagen I and Enhances Chemothera… DOI 10.1177/15473287261442512↗
- Paper Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic… DOI 10.1002/mco2.70829↗
- Yuejuan Cheng · 5 shared papers, 2023–2026 · strength 1.28
- Paper Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. DOI 10.1177/17588359261470681↗
- Paper Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic… DOI 10.1002/mco2.70829↗
- Paper S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-pacli… DOI 10.1177/17588359251378698↗
- Hui Jun Tang · 4 shared papers, 2023–2026 · strength 0.99
- Paper Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. DOI 10.1177/17588359261470681↗
- Paper S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-pacli… DOI 10.1177/17588359251378698↗
- Paper A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line … DOI 10.1186/s12885-023-11464-3↗
- Yingyi Wang · 3 shared papers, 2025–2026 · strength 0.88
- Paper Adjuvant FOLFIRINOX versus S-1 monotherapy for resected PDAC: retrospective real-world data. DOI 10.1177/17588359261470681↗
- Paper Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic… DOI 10.1002/mco2.70829↗
- Paper S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-pacli… DOI 10.1177/17588359251378698↗
- Hui Tang · 3 shared papers, 2025–2026 · strength 0.87
- Paper Inhibition of Gemcitabine-Induced Autophagy in Cancer-Associated Fibroblasts Reduces Collagen I and Enhances Chemothera… DOI 10.1177/15473287261442512↗
- Paper Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic… DOI 10.1002/mco2.70829↗
- Paper [Comparison of adjuvant S-1 plus gemcitabine with S-1 monotherapy for pancreatic adenocarcinoma: real-world data]. DOI 10.3760/cma.j.cn112152-20250310-00103↗
- Dongfeng Song · 2 shared papers, 2026 · strength 0.60
- Paper Inhibition of Gemcitabine-Induced Autophagy in Cancer-Associated Fibroblasts Reduces Collagen I and Enhances Chemothera… DOI 10.1177/15473287261442512↗
- Paper Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic… DOI 10.1002/mco2.70829↗
- Yingyi Wang · 2 shared papers, 2023–2024 · strength 0.40
- Paper A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line … DOI 10.1186/s12885-023-11464-3↗
- Paper The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer. DOI 10.1007/s11764-023-01429-7↗
- Robert Chunhua Zhao · 1 shared paper, 2026 · strength 0.32
- Huanwen Wu · 1 shared paper, 2025 · strength 0.26
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.